Drug Profile
JNJ 39220675
Alternative Names: JNJ-39220675Latest Information Update: 18 Aug 2015
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Antiallergics; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 08 Dec 2008 Phase-II clinical trials in Seasonal allergic rhinitis in Canada (PO)